Literature DB >> 3537119

Comparative pathogenicity and antigenic cross-reactivity of Rift Valley fever and other African phleboviruses in sheep.

R Swanepoel, J K Struthers, M J Erasmus, S P Shepherd, G M McGillivray, A J Shepherd, D E Hummitzsch, B J Erasmus, B J Barnard.   

Abstract

Homologous and heterologous haemagglutination-inhibition (HAI), complement-fixation (CF), immunodiffusion (ID) and mouse neutralization tests were performed with the Lunyo (LUN) and a Zimbabwean strain of Rift Valley fever (RVF) virus, the prototype and a South African strain of Arumowot (AMT) virus and prototype strains of Gordil (GOR), Saint-Floris (SAF) and Gabek Forest (GF) viruses, using immune mouse ascitic fluids prepared against these viruses. Reactions of identity occurred in all tests between LUN and the Zimbabwean strains of RVF and between the two strains of AMT virus. Otherwise, cross-reactions occurred between all the phleboviruses in HAI tests, while reactions in CF, ID and neutralization tests were monospecific for virus serotypes, except that weak cross-reaction occurred between GOR and SAF viruses in CF and ID tests. Four sheep infected subcutaneously with the Zimbabwean strain of RVF virus developed transient fever, viraemia, leucopaenia, relative thrombocytopaenia, haemoconcentration and raised serum enzyme levels, which indicated that the sheep had developed necrotic hepatitis. Disseminated focal necrotic hepatitis was confirmed in a sheep killed for examination on day 4 post-infection. The other three sheep recovered uneventfully after only mild depression and anorexia. Groups of three sheep infected with SAF, GOR, AMT and GF viruses had no demonstrable viraemia or other sign of infection or illness, except that the sheep infected with AMT developed mild fever lasting less than 24 h. Antibody responses were monitored at intervals over a period of 24 weeks in all sheep by homologous and heterologous HAI, CF and cell culture neutralization (CPENT) tests. Homologous antibody responses were marked in the RVF-infected sheep and their sera cross-reacted strongly in HAI tests with antigens of the other viruses. The sera of the RVF-infected sheep cross-reacted less markedly in CF and CPENT tests. Homologous antibody responses were poor in all the sheep infected with phleboviruses other than RVF, and the cross-reactivity of their sera for RVF antigen or virus was negligible. All sheep were challenged with RVF virus 48 weeks after their initial infection. The sheep which had originally been infected with RVF virus were immune and developed neither fever nor viraemia. All other sheep developed fever, viraemia and antibodies to RVF virus. It was concluded that the African phleboviruses, other than RVF, are unlikely to cause disease in livestock or to induce antibodies which could cause confusion in the diagnosis of RVF.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3537119      PMCID: PMC2083542          DOI: 10.1017/s0022172400065426

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  16 in total

1.  A variant of Rift Valley fever virus.

Authors:  M P WEINBREN; M C WILLIAMS; A J HADDOW
Journal:  S Afr Med J       Date:  1957-09-21

2.  Studies on the epidemiology of Rift Valley Fever.

Authors:  R Swanepoel
Journal:  J S Afr Vet Assoc       Date:  1976-06       Impact factor: 1.474

3.  Serological relation between Rift Valley fever virus and viruses of phlebotomus fever serogroup.

Authors:  R E Shope; C J Peters; J S Walker
Journal:  Lancet       Date:  1980-04-19       Impact factor: 79.321

4.  Seriologic and vector comparisons of Rift Valley virus with other bunyaviruses.

Authors:  R E Shope
Journal:  J Egypt Public Health Assoc       Date:  1978

5.  A modified sedimentation method for counting platelets in blood.

Authors:  R K Archer; B V Allen; C Baldwin
Journal:  Br J Haematol       Date:  1978-03       Impact factor: 6.998

6.  Genotypic varieties of La Crosse virus isolated from different geographic regions of the continental United States and evidence for a naturally occurring intertypic recombinant La Crosse virus.

Authors:  R A Klimas; W H Thompson; C H Calisher; G G Clark; P R Grimstad; D H Bishop
Journal:  Am J Epidemiol       Date:  1981-07       Impact factor: 4.897

7.  Analyses of Patois group Bunyaviruses: evidence for naturally occurring recombinant Bunyaviruses and existence of immune precipitable and nonprecipitable nonvirion proteins induced in Burnyavirus-infected cells.

Authors:  H Ushijima; M Clerx-van Haaster; D H Bishop
Journal:  Virology       Date:  1981-04-30       Impact factor: 3.616

8.  Use of sarcoma 180/TG to prepare hyperimmune ascitic fluid in the mouse.

Authors:  A C Sartorelli; D S Fischer; W G Downs
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

9.  Recombination and complementation between temperature-sensitive mutants of a Bunyavirus, snowshoe hare virus.

Authors:  J Gentsch; D H Bishop
Journal:  J Virol       Date:  1976-10       Impact factor: 5.103

10.  Clinical, virological and serological response of the West African dwarf sheep to experimental infection with different strains of Rift Valley fever virus.

Authors:  O Tomori
Journal:  Res Vet Sci       Date:  1979-03       Impact factor: 2.534

View more
  19 in total

1.  Development and evaluation of a real-time reverse transcription-loop-mediated isothermal amplification assay for rapid detection of Rift Valley fever virus in clinical specimens.

Authors:  C A Le Roux; T Kubo; A A Grobbelaar; P Jansen van Vuren; J Weyer; L H Nel; R Swanepoel; K Morita; J T Paweska
Journal:  J Clin Microbiol       Date:  2008-12-24       Impact factor: 5.948

2.  Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep.

Authors:  Bonto Faburay; William Wilson; D Scott McVey; Barbara S Drolet; Hana Weingartl; Daniel Madden; Alan Young; Wenjun Ma; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2013-08-20       Impact factor: 2.133

3.  Evaluation of an Indirect Enzyme-Linked Immunosorbent Assay Based on Recombinant Baculovirus-Expressed Rift Valley Fever Virus Nucleoprotein as the Diagnostic Antigen.

Authors:  Bonto Faburay; William C Wilson; Arss Secka; Barbara Drolet; D Scott McVey; Juergen A Richt
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

4.  The genetic basis for susceptibility to Rift Valley fever disease in MBT/Pas mice.

Authors:  S Tokuda; T Z Do Valle; L Batista; D Simon-Chazottes; L Guillemot; M Bouloy; M Flamand; X Montagutelli; J-J Panthier
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

5.  Preparation and evaluation of recombinant severe fever with thrombocytopenia syndrome virus nucleocapsid protein for detection of total antibodies in human and animal sera by double-antigen sandwich enzyme-linked immunosorbent assay.

Authors:  Yongjun Jiao; Xiaoyan Zeng; Xiling Guo; Xian Qi; Xiao Zhang; Zhiyang Shi; Minghao Zhou; Changjun Bao; Wenshuai Zhang; Yan Xu; Hua Wang
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

6.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

7.  Serological and genomic evidence of Rift Valley fever virus during inter-epidemic periods in Mauritania.

Authors:  M Rissmann; M Eiden; B O El Mamy; K Isselmou; B Doumbia; U Ziegler; T Homeier-Bachmann; B Yahya; M H Groschup
Journal:  Epidemiol Infect       Date:  2016-12-28       Impact factor: 4.434

8.  Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice.

Authors:  Petrus Jansen van Vuren; Caroline T Tiemessen; Janusz T Paweska
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

9.  Rift Valley fever in goats, Cameroon.

Authors:  Matthew LeBreton; Sally Umlauf; Cyrille F Djoko; Peter Daszak; Donald S Burke; Paul Yemgai Kwenkam; Nathan D Wolfe
Journal:  Emerg Infect Dis       Date:  2006-04       Impact factor: 6.883

10.  Rift valley fever in humans and animals in Mayotte, an endemic situation?

Authors:  Tinne Lernout; Eric Cardinale; Maël Jego; Philippe Desprès; Louis Collet; Betty Zumbo; Emmanuel Tillard; Sébastien Girard; Laurent Filleul
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.